System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Jamie Duckers is an expert in Pulmonology at University Hospital Llandough (United Kingdom). As of September 2026, ScienceLeadR ranks Jamie Duckers in the top 1% of experts worldwide for Cystic Fibrosis and Pancreatic Diseases. Jamie Duckers has authored 199 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 2 of them ongoing. SLR score: 737 (community average: 125). How the SLR is computed.

LeadR Profile

Jamie Duckers University Hospital Llandough United Kingdom
737 ScienceLeadR Reputation 737

Unlock

Register Login
Network Map

Pulmonology

Subspecialties: Nephrology - Public Health - Pediatrics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2010 - 2026
Source: PubMed

University Hospital Llandough

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 199

Citations

Citations: 1 848 1st author: 8 Last author: 93 Unique author: 1

Main journals

J Cyst Fibros 129
Lancet Respir Med 5
ERJ Open Res 4
Lung Cancer 4
Eur Respir J 3

Best Journals

Lancet Respir Med 5
N Engl J Med 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Effects of hypertonic saline and/or carbocisteine on sputum rheology in bronchiectasis: CLEAR-EME.
PMID 42769362 — rheology, biomarkers, sputum, therapeutics, bronchiectasis		ERJ Open Res20260
Resource impact of bronchiectasis and associated exacerbations: based on a 5-year prospective observational cohort study (BronchUK).
PMID 42448374 — cohort studies, bronchiectasis		BMJ Open Respir Res20260
Clinical characteristics and outcomes in the adult cystic fibrosis population in Europe from 2014 to 2024: analysis of the European Cystic Fibrosis Society Patient Registry.
PMID 42235564 — registries, fibrosis, cystic fibrosis transmembrane conductance regulator, cystic fibrosis, therapeutics		Lancet Respir Med Top journal20260
Remodelling of cystic fibrosis respiratory microbiota in response to extended elexacaftor-tezacaftor-ivacaftor therapy.
PMID 42218569 — fibrosis, cystic fibrosis, azithromycin, therapeutics, microbiota		Microbiome20260
Guidance for Chest-CT in Children and Adults with Cystic Fibrosis: A European Perspective (Part 2: Special Situations/Respiratory Complications).
PMID 42190839 — fibrosis, respiratory tract diseases, cystic fibrosis, child		Respir Med20260

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

N/A 3
Phase 3 2

By status:

Completed 3
Recruiting 2

By type:

Interventional 3
Observational 2

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 1
multicentricup10 3

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Understanding Inflammation InFection and Interventions in Severe Exacerbations of Cystic Fibrosis
NCT07484607 — fibrosis, cystic fibrosis, sputum, pulmonary fibrosis, therapeutics, infections		N/ARecruiting2025
Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis
NCT06940531 — fibrosis, cystic fibrosis, pulmonary fibrosis, risk factors		N/ARecruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS